

Brief Biographies
Governing Board of the California Institute for Regenerative
Medicine (*the Independent Citizens Oversight Committee*)
May 2010

Ricardo Azziz, M.D., MPH, M.B.A.

An executive officer from a California Research Institute (1 of 4), appointed by the Governor

Ricardo Azziz, MD, MPH, MBA, is Chairman of the Department of Obstetrics and Gynecology at Cedars-Sinai Medical Center. Dr. Azziz also serves as Professor, In-Residence at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA) and Vice Chair of the Department of Obstetrics and Gynecology at UCLA.

Certified by the American Board of Obstetrics and Gynecology, Dr. Azziz has special certification in reproductive endocrinology and infertility. His current research interests involve the treatment of infertility and hormonal disorders in women, particularly androgen excess disorders, hirsutism and polycystic ovary syndrome. Dr. Azziz's interests also extend to the use of endoscopy for pelvic reconstruction. His investigations have received funding from the March of Dimes, the National Institutes of Health and from pharmaceutical companies.

In addition to writing over 100 peer-reviewed articles, Dr. Azziz has written numerous book chapters and has co-edited several books. Dr. Azziz is a fellow of the American College of Obstetrics and Gynecology, a fellow of the American College of Surgeons and a member of the Board of Directors of the Society for Reproductive Surgeons, as well as a member of the American Society for Reproductive Medicine and The Endocrine Society. He is also Vice Chair of the FDA Advisory Committee for Reproductive Health Drugs.

Dr. Azziz received his bachelor's degree from the University of Puerto Rico in Mayaguez and his medical degree from Pennsylvania State University College of Medicine in Hershey. After his internship and residency in obstetrics and gynecology at Georgetown University Hospital, he completed his fellowship in reproductive endocrinology at Johns Hopkins University School of Medicine. Dr. Azziz earned his Master of Public Health degree in general theory and practice at the University of Alabama, Birmingham School of Public Health and his Master of Business Administration at the University of Alabama, Birmingham School of Business.

Robert Birgeneau, Ph.D.

An executive officer from a California University (1 of 4), appointed by the Lt. Governor

An internationally distinguished physicist, Robert Birgeneau, Ph.D., is chancellor of UC Berkeley. Birgeneau's research focuses on understanding the fundamental properties of materials beginning at the level of a single atom and building up to macroscopic dimensions. His work has earned him numerous citations and awards, including the O.E. Buckley Prize of the American Physical Society and the H.E. Lilienfeld Prize of the American Physical Society.

A Toronto native and the first in his family to finish high school, Birgeneau received his B.Sc. in mathematics from the University of Toronto in 1963 and his Ph.D. in physics from Yale University in 1966. He served on the faculty of Yale for one year and then spent one year at Oxford University. He was a member of the technical staff at Bell Laboratories from 1968 to 1975 and then joined MIT as a professor of physics, spending 25 years on the faculty there. He was named head of the physics department in 1988 and in 1991 was appointed dean of science. He became the 14th president of the University of Toronto on July 1, 2000.

Birgeneau has been elected a foreign associate of the National Academy of Sciences, has received numerous awards for teaching and research, and is one of the most highly cited physicists in the world. He was elected a fellow of the Royal Society of London in 2001 and the Royal Society of Canada in 2002. A leader on gender issues within higher education, Birgeneau is well known for his commitment to diversity and equity in the academic community.

Floyd E. Bloom, M.D.

An executive officer from a California University (2 of 4), appointed by the Treasurer

Floyd Bloom, an internationally renowned neuroscientist, is Executive Director, Science Communication at The Scripps Research Institute, where he is also Professor Emeritus in the Department of Molecular and Integrative Neurosciences. Bloom has more than 40 years of medical practice and research experience. Since 1983, he has been a professor at The Scripps Research Institute, where he served as chairman of the Department of Neuropharmacology from 1989 to 2000 and again from 2002 to 2005. He also co-founded Neurome, a La Jolla-based biotechnology company dedicated to the discovery and development of solutions for human neurodegenerative diseases.

From 1995 to 2000, Bloom served as Editor-in-Chief of *Science*, the premier journal of scientific thought and discovery. His prior positions included director of behavioral neurobiology at the Salk Institute, chief of the neuropharmacology laboratory at the National Institute of Mental Health and president of the American Association for the Advancement of Science. Bloom's more than 600 publications include the seminal work, *The Biochemical Basis of Neuropharmacology* and *The Dana Guide to Brain Health*.

A member of the National Academy of Sciences since 1977, Bloom is the recipient of numerous prizes for his contributions to science, including the Janssen Award in the Basic Sciences and the

Pasarow Award in Neuropsychiatry. Bloom is a past chairman of the American Association for the Advancement of Science (AAAS). He has also been named a member of the Royal Swedish Academy of Sciences and a member of the Institute of Medicine.

Bloom received his undergraduate degree from Southern Methodist University in Dallas in 1956 and his M.D. from Washington University in St. Louis in 1960.

David Brenner, M.D.

An executive officer from a UC with a medical school (1 of 5), appointed by UCSD Chancellor

David Brenner, M.D., a distinguished physician-scientist who began his academic career at UC San Diego, is Vice Chancellor for Health Sciences and Dean of the School of Medicine at UC San Diego. Brenner leads the UC San Diego School of Medicine, Skaggs School of Pharmacy and Pharmaceutical Sciences, UCSD Medical Center and UCSD Medical Group. He has oversight of over 900 health sciences faculty physicians, pharmacists and scientists; 7,500 staff; more than 600 medical and pharmacy students; and a health system that cares for approximately 125,000 patients annually.

Brenner is a leader in the field of gastroenterological research, specializing in diseases of the liver. He is widely known and respected as a translational scientist whose work bridges the laboratory and the clinical setting. He has focused on understanding the molecular pathogenesis of fibrotic liver disease and the genetic basis of liver disorders as the foundation for improving prevention and treatment of diseases of this organ. He is also recognized as an outstanding clinician and teacher.

For five years he was Editor-in-Chief of Gastroenterology, the premier journal in the field. After earning his M.D. from the Yale University School of Medicine and completing his residency at Yale-New Haven Medical Center, Brenner was a research associate in the Genetics and Biochemistry Branch of the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases of the National Institutes of Health. He first came to UC San Diego in 1985 on a fellowship in gastroenterology, later joining the faculty of UC San Diego School of Medicine, and serving as a physician at the Veterans Affairs San Diego Healthcare System. He became a Pew Scholar in the Biomedical Sciences and a Clinical Investigator in the VA system. He left UC San Diego in 1992 to become Professor and Chief of the Division of Digestive Diseases and Nutrition at the University of North Carolina at Chapel Hill, where he continued to earn accolades for his patient care and research contributions. Brenner became the Samuel Bard Professor and Chair of the Department of Medicine at Columbia University Medical Center, College of Physicians and Surgeons, and Physician-in-Chief of New York Presbyterian Hospital/ Columbia in 2003.

Brenner's professional associations include the American Society for Clinical Investigation, the Association of American Physicians, for which he is the secretary, the American College of Physicians, and the American Gastroenterological Association, for which he is chair of the Research Policy Committee, and the American Clinical and Climatological Association. He is also on the board of directors of two philanthropic foundations, the AlphaOne Foundation and the Alcoholic Beverage Medical Research Foundation.

Dr. William R. Brody, M.D., Ph.D.

An executive officer from a California Research Institute (2 of 4), appointed by the Lt. Governor

Dr. William R. Brody, an acclaimed physician-scientist, entrepreneur and university leader, joined the Salk Institute for Biological Studies on March 2, 2009 after 12 years as president of The Johns Hopkins University. He is a national figure in efforts to encourage innovation and strengthen the U.S. economy through investments in research and education. Most recently, he has written and spoken extensively around the country to promote a fuller discussion of health care reform.

Renowned for his achievements in biomedical engineering, Dr. Brody is a member of the National Academy of Engineering and the Institute of Medicine. He is also an accomplished scientist authoring more than 100 articles in U.S. medical journals. His has made significant contributions to the fields of medical acoustics, computed tomography, digital radiography, and magnetic resonance imaging. Dr. Brody holds two U.S. patents in medical imaging and is the co-founder of three medical device companies.

Dr. Brody's scientific advancements in the medical instrumentation field have led to his induction into and recognition by many national organizations. He is a fellow of the Institute of Electrical and Electronic Engineers (IEEE); the American Academy of Arts and Sciences; the American Institute of Biomedical Engineering; the International Society of Magnetic Resonance in Medicine; the American Heart Association; the American College of Radiology; and the American College of Cardiology.

Before being named president of The Johns Hopkins University in 1996, he served as provost of the Academic Health Center at the University of Minnesota for two years. Prior to that, he held appointments at The Johns Hopkins University School of Medicine from 1987 to 1994, including the Martin Donner Professor and Director of the department of Radiology; professor of Electrical and Computer Engineering; professor of Biomedical Engineering; and Radiologist-in-Chief of The Johns Hopkins Hospital.

Prior to his career at Johns Hopkins, he held appointments at the Stanford University School of Medicine from 1977 to 1986, including Professor of Radiology and Electrical Engineering; Director, Advanced Imaging Techniques Laboratory; Associate Professor of Radiology and Electrical Engineering; and Director of Research Laboratories, Division of Diagnostic Radiology.

A native of Stockton, Calif., Dr. Brody received his bachelor's and master's degrees in electrical engineering from the Massachusetts Institute of Technology. He received his doctorate (also in electrical engineering) and his medical degree (M.D.) from Stanford University.

He continued his post-graduate training in cardiovascular surgery and radiology at Stanford, the National Institutes of Health, and the University of California at San Francisco. The Canadian Association of Radiologists recognized Dr. Brody's contributions by making him an honorary member in 1974. He is also the recipient of the Outstanding Alumnus Award from UC San Francisco's department of Radiology; the American Heart Association's Established Investigator Award; and the Western Thoracic Surgical Society Prize Manuscript Award.

He currently serves on a number of national boards, including: IBM; Stanford University; and Novartis. He is on the FBI's National Security Higher Education Advisory Board, and is a member of the executive committee of the Council on Competitiveness. He formerly served on the President's Foreign Intelligence Advisory Board and on the Corporation of the Massachusetts Institute of Technology.

Susan V. Bryant, Ph.D.

An executive officer from a UC with a medical school (2 of 5), appointed by UCI Chancellor

Susan V. Bryant, Ph.D., is a developmental biologist who during her career has conducted influential research in the area of regeneration and has published more than 100 papers delineating its core principles in addition to pioneering the development of molecular techniques for studying regenerative systems.

Dean of the School of Biological Sciences at the University of California, Irvine (UCI), Dr. Bryant rose to the position after being the first woman in the university's history to be recruited as a faculty member in biology. Since then, she has continued to be a strong advocate for women in science, winning numerous awards including the UCI Pacesetter Award for contributions to women. Her goal as Dean is to ensure that the School is a major participant in the discoveries that are fueling the revolution in biology, and at the same time to work for the full participation of women and minorities in the scientific enterprise.

Dr. Bryant has been an influential developmental biologist, and she established regeneration as a model system for pattern formation. Her research provided evidence for a unified model for pattern formation, demonstrated the universality of regulative mechanisms among diverse animals, predicted the conservation of developmental pathways, and pioneered the development of molecular techniques for studying regenerating systems.

Dr. Bryant spent her childhood in Yorkshire, UK. She became interested in biology in at a girls-only high school, obtained her undergraduate degree at King's College and her Ph.D. degree at St. Mary's Hospital Medical School, University of London. She moved to the US to study regeneration as a postdoctoral fellow at Case Western Reserve University, after which she joined the faculty at UC Irvine. In 2005, she was elected a Fellow, the highest honor bestowed, by the Association for Women in Science.

Marcy Feit, RN, MSN

***Patient Advocate (1 of 10), appointed by the Lt. Governor
Type II Diabetes***

Marcy Feit joined ValleyCare Health System in 1973. After earning her RN credentials, she worked in the critical care unit for three years followed by a 3-year stint as the unit's head nurse. A series of promotions to administrative positions followed. In 1995, Marcy became Vice President

of Patient Care Services. In December 1996, she became Chief Operating Officer and Interim Chief Executive Officer.

In July 1997, Marcy was appointed President and Chief Executive Officer of ValleyCare Health Systems.

She holds a Master's Degree in Nursing Science and Administration and has served on a state strategic planning committee for nursing, the Medical/Auxiliary Advisory Committee for Chabot College, and the Board of Directors for Hope Hospice. She is currently a member of the Tri-Valley Business Council, and serves as a member of the East Bay Hospital Council. She is also a member of the Board of Directors for Cooperative Hospitals, Inc., VHA West Coast, and Sigma Theta Tau, International.

Other accomplishments:

1998 Women of Achievement Award, Contra Costa County;
2003 San Francisco Times Top 100 Business Women of the Year
2003 Distinguished Alumna – Community College League of California
2004 Mertes-Feit Chabot Las Positas ValleyCare Education Center
2004 San Francisco Business Times Top 100 Business Women of the Year
2005 TriValley Magazine Ten Most Powerful Women

Michael A. Friedman, M.D.

An executive officer from a California Research Institute (3 of 4), appointed by the Treasurer

Dr. Michael Friedman is President and Chief Executive Officer of City of Hope, a cancer research and treatment institution dedicated to innovation in basic and clinical biomedical research and delivery of compassionate, world-class patient care. Dr. Friedman was formerly senior vice president of research and development, medical and public policy, for Pharmacia Corporation. In addition, he served as chief medical officer for biomedical preparedness at the Pharmaceutical Research and Manufacturers of America following the events of September 11, 2001. Dr. Friedman had previously served as FDA Deputy Commissioner and was later tapped by the Clinton administration to serve as acting commissioner of the agency. He helped to streamline the FDA's review and approval process and provided oversight of evaluations for drugs, biologics, medical devices and food ingredients.

In 1983, Dr. Friedman was chief of the Clinical Investigations Branch of the Division of Cancer Treatment at the National Cancer Institute, and went on to become associate director of the Division's Cancer Therapy Evaluation Program. Before joining the NCI, Dr. Friedman spent nearly a decade at the University of California at San Francisco, serving as associate professor of medicine, eventually becoming interim director of the Cancer Research Institute.

Dr. Friedman has received numerous commendations, including the Surgeon General's Medallion in 1999. He received his Bachelor of Arts degree, magna cum laude, from Tulane University and a Doctorate in Medicine from the University of Texas. He completed postdoctoral training at

Stanford University and the National Cancer Institute, and is board certified in Internal Medicine and Medical Oncology.

Leeza Gibbons

***Patient Advocate (2 of 10), appointed by the Governor
Alzheimer's Disease***

For all of her accomplishments in the worlds of radio and television, Leeza Gibbons is most comfortable being called a “storyteller”. Her 30 years in the public consciousness has allowed her to be a conduit through which information and ideas find their way into the marketplace. Through it all, her focus is empowerment and adding value through her products and programs to enhance the lives of women and their families.

From television news journalist and host, to radio personality, producer and businesswoman, Leeza Gibbons has been entering America's living rooms for 3 decades. While she would nationally burst on the scene as an anchor & reporter on ENTERTAINMENT TONIGHT, it wouldn't be until hosting her own daytime talker LEEZA that audiences would see Gibbons' determination to get outside of the box and become a household name while highlighting her intelligence, sensitivity and compassion. Gibbons served as Executive Producer of LEEZA, which debuted on NBC in 1994 and continued nationally through 2000. It was during the series run that Gibbons' impact on television would be awarded with one of Hollywood's highest honors: a star on the Hollywood Walk of Fame. Gibbons formed LEEZA GIBBONS ENTERPRISES (LGE) in 1994, and since then she has produced and developed the kinds of projects, partnerships and products that reflect her passions and concerns.

Most recently, Leeza participated in season four of ABC's hit show DANCING WITH THE STARS, dedicating her performances to her children and to her mother and other families struggling with Alzheimer's disease. Leeza hosts and produces the nationally syndicated radio program HOLLYWOOD CONFIDENTIAL which is featured on over 125 radio stations across the country and is now entering its 15th year in production. A recent venture, SHEER INSPIRATION LIFE COACHING, is an innovative web business which supplies users with a personal coach via email and/or phone to tackle a variety of challenges ranging from parenting and health to relationships.

In 2002, Leeza Gibbons launched SHEER COVER, her mineral based makeup line, allowing her to continue her intimate relationships with women by offering empowerment and focusing on inner beauty and the things that matter most.

It was a need to serve her own family that prompted Gibbons to leave her daily post as managing editor and host of the newsmagazine EXTRA in 2003 to form THE LEEZA GIBBONS MEMORY FOUNDATION (a 501c3, non-profit) - her most personal endeavor to date. Through its signature program called LEEZA'S PLACE, the foundation offers free services and support to caregivers and those newly diagnosed with neurological disorders. Located in cities from coast to coast, there are currently eight locations. LEEZA'S PLACE fulfills Leeza's promise to her mother to “take her story, and make it count” after her diagnosis with Alzheimer's disease.

Leeza Gibbons leads a life of gratitude and while thrilled with all of her many professional & philanthropic accomplishments, she is most proud of her own family life. She has three children: daughter Lexi (18), and sons Troy (15) and Nathan (10).

Michael D. Goldberg

An executive officer of a Commercial Life Science Entity (1 of 4), appointed by the Treasurer

As a general partner at MDV Michael leverages valuable entrepreneur and investor experience from his more than 20 years of work in the life sciences industry including biotechnology, pharmaceuticals, health services and healthcare information technology. In addition to pursuing life sciences investments for MDV he works to extend the firm's reach into major universities and research centers.

Prior to joining MDV Michael was Managing Director of Jasper Capital and Co-chair of the California Research and Cures Coalition (\$3 billion Prop 71 stem cell campaign). He has also held senior management and operations roles including serving as Chairman of OnCare, an oncology practice management company he founded in 1995. Until 1999 he also served as OnCare's Chief Executive Officer, where he guided revenue growth to \$100 million in three years.

Previously, Michael was Founder and Chief Executive Officer of Axion Inc., a cancer-focused healthcare service company he started in 1987 and sold to Bristol-Myers Squibb in 1996. Axion ranked number four on Inc. Magazine's list of the 500 fastest growing private companies in America for the five years ended 1994. Michael was also a recipient of Inc. Magazine's 1995 Entrepreneur of the Year Award. Prior to his tenure with Axion, Michael was a partner in the venture capital firm Sevin Rosen Funds, where he was responsible for the firm's investments in the biomedical industry.

Michael is a member of the executive committee of the board of trustees of the National Childhood Cancer Foundation and is on the Advisory Council of the Stanford Neuroscience Institute. He received a B.A. from Brandeis University and an M.B.A. from Stanford Graduate School of Business.

Sam Hawgood, M.B. B.S.

An executive officer from a UC with a medical school (3 of 5), appointed by UCSF Chancellor

Dr. Sam Hawgood is currently the Dean of the School of Medicine, and Vice Chancellor for Medical Affairs at the University of California San Francisco (UCSF). Hawgood graduated with First Class Honors from the University of Queensland in Australia in 1975. After graduation, he trained in Australia in pediatrics with a sub-speciality interest in neonatology. Hawgood moved to UCSF in 1982 to work with Drs. Tooley and Clements, pioneers in the discovery and therapeutic uses of pulmonary surfactant in premature babies.

Pulmonary surfactant keeps the lungs inflated and a developmental deficiency of surfactant is the major cause of the respiratory distress syndrome of the newborn (RDS). Hawgood's interest in the

biology of surfactant grew from clinical experience in neonatology where RDS is a major cause of neonatal death. He moved to UCSF in 1982 as a research fellow with Lasker Awardee, Dr. John Clements, the scientist that discovered surfactant in the late 1950's. Hawgood started his own laboratory, focused on the proteins associated with surfactant, in 1984. A multi-disciplinary Program Project Grant from the National Heart, Lung and Blood Institute has supported his work since 1984. His scientific contributions over the last 25 years have been recognized by numerous invitations to present in national and international forums and continuous funding from the National Institutes of Health.

Hawgood has maintained an active presence in clinical medicine, serving as Division Chief of Neonatology at UCSF from 1994 to 2006. He has been an Associate Director of the CVRI since 1997, and was Chair of Pediatrics and Physician-in-Chief of the UCSF Children's Hospital from 2003 to 2009. He is also currently President of the UCSF Medical Group, the faculty plan representing more than 1,500 physicians at UCSF.

In service to professional organizations Hawgood served on the Council of the Society for Pediatric Research for seven years between 1992 and 2000 and was President of the Society in 1999. He chaired the Program Committee for the Pediatric Academic Societies from 1998-2000 and in 2005 received the Distinguished Service Award from the Society for Pediatric Research. He was a Trustee and Secretary-Treasurer of the International Pediatric Research Society from 2003 to 2009. Hawgood has served on study sections for the NIH and is currently a member of the Program Project Parent Committee of the National Heart, Lung, and Blood Institute. In addition, Dr. Hawgood was recently elected to the Institute of Medicine (IOM), part of the National Academy of Sciences.

Robert Klein, J.D.

Chair, Governing Board of the CIRM (Independent Citizens Oversight Committee)

Robert N. Klein's commitment to advancing medical research originated in his younger son Jordan's diagnosis with Juvenile Diabetes in 2001. In addition, his mother was diagnosed with Alzheimer's two years earlier. In 2002, Bob was a principal negotiator, as a part of a Juvenile Diabetes Research Foundation patient advocate team that worked successfully to pass a \$1.5 billion mandatory federal funding bill for an additional five years of Type 1 and Type 2 diabetes supplemental National Institutes of Health research funding. In 2003, Bob served as the author and Chairman of California's Proposition 71, the \$6 billion "California Stem Cell Research and Cures" ballot initiative. Currently he serves as the Chairman of the Governing Board of the California Institute of Regenerative Medicine established by Proposition 71 to manage the peer review, standards, and grant process for the \$3 billion in stem cell research funding authorized by the proposed Initiative.

Time Magazine honored Bob as "one of the World's 100 Most Influential People of the Year" for 2005. Soon after, Scientific American named Bob one of "The Scientific American 50" as a leader shaping the future of science. In March 2010, Research!America honored Bob for his work in patient advocacy with the Gordon & Llura Gund Leadership Award. Most recently, Bob received the Biotech Humanitarian Award at the BIO International Convention in May 2010.

In other civic activities, Bob served for six years as a board member for the State of California Housing Finance Agency which has approximately \$8 billion in financing outstanding, an S&P Bond rating of AA, and a history of receiving national awards in almost every category of affordable housing. This public corporation of the State of California was created by legislation in 1976, which Bob conceptualized, proposed and managed as the principal consultant to the California State Assembly and State Senate Joint Committee on Housing and Urban Renewal.

Bob serves on the Board of Directors of the International Juvenile Diabetes Research Foundation and he has recently retired from the Board of Genome Canada, a Canadian government genomic and proteomic research agency with \$1.4 billion in authorized research. He was co-chair of the Stem Cell and Regenerative Medicine Working Group of the Canada-California Strategic Innovation Partnership, the working group which initiated the Cancer Stem Cell Consortium in Canada, a strategic partner of the California Institute for Regenerative Medicine. Bob also serves on the Board of the Global Security Institute, dedicated to reducing the global risks from nuclear weapons. His accomplishments include, in addition to writing the California Housing Finance Agency Act, the development of California's first tax credit National Historic Site Restoration Project and development of California's first local governmental, tax-exempt, bond-financed, affordable apartment project.

Bob has also served as the Vice-president of the board of directors of the State of the World Forum, an international organization focused on global economic development.

Bob has a Bachelor of Arts in History with Honors from Stanford University and a Juris Doctorate from Stanford Law School. He retired as a captain from the United States Air Force.

While attending law school, Bob taught an undergraduate seminar entitled "Three Case Studies in Political Reform: Judicial Interpretation of Civil Liberties; Environmental Regulations; and, Housing Programs Under the 1968 Omnibus Housing Bill." He also served as an instructional leader and coordinator of a law school seminar entitled "Legal Systems, Civil Disobedience and the Ghetto." Bob held an internship with the United Nations Economic and Social Council in Switzerland where he focused on Economic Development Policy. He is the President of Klein Financial Corporation, a real estate investment banking consulting company focused on affordable housing finance and development with a record of approximately \$3 billion in financing, financial consulting, and developing public and private projects. Klein Financial Corporation has never obtained any financing from the California Housing Finance Agency.

Bob Klein is a member of both the California Bar Association and the American Bar Association. He lives in Northern California with his wife, Danielle Guttman-Klein, and has four children: Lauren, Robert, Jordan and Alyssa.

Examples of Awards and Recognition:

Biotech Humanitarian Award at the BIO International Convention (2010); Research!America, "Gordon and Llura Gund Leadership Award" (2010); The Commonwealth Club, "Distinguished Citizen Award" (2006); The Harvard Club, "Public Service Leader of the Year" (2006); Juvenile Diabetes Research Foundation, "Living and Giving Award" (2005); Alliance for Aging Research,

“Alan Cranston Living Legend Award” (2005); as well as Proclamations from the California Legislature.

Sherry Lansing

***Patient Advocate (3 of 10), appointed by the Controller
Cancer***

Founder and current chair of the Sherry Lansing Foundation, a philanthropic organization focusing on cancer research, health and education, Ms. Lansing was the chair of the Motion Picture Group of Paramount Pictures from 1992 to 2005, where she oversaw the release of more than 200 films including Academy Award winners *Forrest Gump*, *Braveheart*, and highest grossing movie of all time, *Titanic*. A pioneering studio executive, Lansing is the first woman in the film industry to oversee all aspects of a studio’s motion picture production.

Her distinguished career has earned her numerous honors, including the Woodrow Wilson Award for Corporate Citizenship, the Milestone Award from the Producers Guild of America, the Overcoming Obstacles Achievement Award for Business, the YWCA Silver Achievement Award, the Outstanding Woman in Business Award from the Women’s Equity Action League, the Distinguished Community Service Award from Brandeis University, the Alfred P. Sloan, Jr. Memorial Award and an honorary Doctorate in Fine Arts from the American Film Institute. She was also the recipient of the Simon Wiesenthal Center Distinguished Service Award for the Performing Arts and was named the 1996 Pioneer of the Year by the Foundation of the Motion Picture Pioneers. In 2004, Lansing received the Horatio Alger Humanitarian Award.

Lansing serves on the Executive Committee of the Board of Directors of Friends of Cancer Research and as a Trustee of the American Association for Cancer Research. She continues to lend her energy and talents to such advisory boards and committees as the American Red Cross Board of Governors, the board of trustees for the Carter Center and Stop Cancer, a non-profit philanthropic group she founded in partnership with Dr. Armand Hammer.

Lansing is a Regent of the University of California and serves as chair of the University Health Services Committee. She graduated cum laude with a Bachelor of Science Degree from Northwestern University in 1966.

Gerald S. Levey, M.D.

An executive officer from a UC with a medical school (4 of 5), appointed by UCLA Chancellor

Dr. Gerald S. Levey, a nationally recognized leader in both academic medicine and private sector medical affairs, is vice chancellor of medical sciences and dean of the David Geffen School of Medicine and holds the academic rank of professor of medicine in the department of medicine. As vice chancellor of medical sciences at UCLA he oversees a diverse medical enterprise including the School of Medicine, UCLA Medical Center, and the UCLA Neuropsychiatric Institute and Hospital.

Dr. Levey joined UCLA in September 1994, having previously served as senior vice president for medical and scientific affairs at Merck & Co., one of the world's leading pharmaceutical companies. He has held major leadership positions throughout his career, including serving as chair of the department of medicine at the University of Pittsburgh School of Medicine from 1979-1991. He is past president of the Association of Professors of Medicine, was a member of the Board of Governors of the American Board of Internal Medicine and is a member of the Association of American Physicians. Dr. Levey is a member of the medical honorary society Alpha Omega Alpha, and is a recipient of the Distinguished Alumnus Award from the University of Medicine and Dentistry of New Jersey and received his Mastership from the American College of Physicians in 1997.

Dr. Levey is an internist and endocrinologist widely known for his research on the thyroid gland and the heart. He was named a Howard Hughes Medical Institute Investigator while at the University of Miami from 1971-1978. Dr. Levey has developed a particular interest in issues of the nation's physician supply and the role of generalist physicians, and served as co-chair of the National Study of Internal Medicine Manpower from 1981-1991.

Ted W. Love, M.D.

An executive officer of a Commercial Life Science Entity (2 of 4), appointed by the Controller

Ted W. Love, M.D. was appointed president and chief executive officer of Nuvelo, Inc. in March 2001, having been appointed president and chief operating officer of the company in January 2001. He has served as a director of the company since February 2001.

Dr. Love joined Nuvelo from Advanced Medicine Inc., where he served as senior vice president of development from February 1998 to January 2001. Previously, Dr. Love spent six years at Genentech Inc., holding a number of senior management positions in Medical Affairs and Product Development. As vice president of Product Development and Regulatory Affairs at Genentech, Dr. Love oversaw all drugs in development including Herceptin, Rituxan, and TNKase. He also served as chairman of Genentech's Product Development Committee.

Dr. Love earned his bachelor's degree in molecular biology from Haverford College and his medical degree at Yale Medical School. He completed his residency and fellowship training in internal medicine and cardiology at Massachusetts General Hospital and Harvard Medical School. Following residency training, Dr. Love joined the faculty of Massachusetts General in the department of cardiology. He also serves as a member of the board of directors for both Predix Pharmaceuticals, Inc. and Santarus, Inc.

Ed Penhoet, Ph.D.

An executive officer of a Commercial Life Science Entity (3 of 4), appointed by the Lt. Governor

Edward E. Penhoet is a Director at Alta Partners, a life sciences venture capital firm. Dr. Penhoet was previously the President of the Gordon and Betty Moore Foundation in San Francisco. Prior to

becoming President, he served as the Foundation's Chief Program Officer for Science and Higher Education Programs.

Dr. Penhoet is the immediate past Dean of the School of Public Health and Professor of Public Health and of Molecular and Cell Biology at the University of California at Berkeley. Since 2000, he has been a director at Alta Partners, a pioneering venture capital firm that focuses on early-stage investing in life sciences, information technology and communications. He is also a director and co-founder of Chiron Corporation, one of the world's leading biotechnology companies. Dr. Penhoet served as Chiron's President and Chief Executive Officer from the time he co-founded the company in 1981 until April 30, 1998.

For 10 years prior to founding Chiron, Dr. Penhoet was a faculty member of the Biochemistry Department of the University of California, Berkeley. While at Chiron, he continued as an adjunct member of the faculty, teaching a variety of courses. In May 1991, Dr. Penhoet received the first Distinguished Faculty Award in the Life Sciences from the department of Molecular and Cell Biology at the University of California, Berkeley. In 1992, Dr. Penhoet shared with Dr. William J. Rutter, a Chiron co-founder, the Northern California Entrepreneur of the Year Award presented by Ernst & Young and Inc. Magazine; in 1994, Penhoet and Rutter received jointly the Harvard Business School Northern California Alumni Chapter award as Entrepreneur of the Year.

Dr. Penhoet earned his A.B. in biology from Stanford University in 1963, and his Ph.D. in biochemistry from the University of Washington in 1968. He was a post-doctoral fellow at the University of California, San Diego, from 1968 to 1970.

Phillip A. Pizzo, M.D.

An executive officer from a California University (3 of 4), appointed by the Controller

Philip A. Pizzo, MD, became dean of the Stanford School of Medicine in April 2001. Before joining Stanford, he was the physician-in-chief of Children's Hospital in Boston and chair of the Department of Pediatrics at Harvard Medical School. Pizzo is recognized for his contributions as a clinical investigator, especially in the treatment of children with cancer and HIV.

Pizzo received his undergraduate degree from Fordham University and an MD from the University of Rochester School of Medicine. He completed an internship and residency at Children's Hospital Medical Center in Boston, a teaching fellowship at Harvard Medical School, and a clinical and research fellowship in pediatric oncology at the National Cancer Institute. Pizzo served as head of the institute's infectious disease section, chief of the NCI's pediatric department, and acting scientific director for NCI's Division of Clinical Sciences.

Pizzo devoted much of his distinguished medical career to the diagnosis, management, prevention and treatment of childhood cancers and the infectious complications that occur in children whose immune systems are compromised by cancer and AIDS. Pizzo and his research team pioneered the development of new treatments for children with HIV infection, lengthening and improving the quality of life for children with this disease. His research soon led to important clues about how to treat HIV-positive children and adults, and how to manage life-threatening infections. In 1988 Pizzo

published the first article in the New England Journal of Medicine on antiviral therapy of HIV in children. He is also the author of more than 500 scientific articles and 14 books.

Pizzo has received several awards from the U.S. Public Health Service, including the Outstanding Service Medal in 1995. He has been cited in Best Doctors of America since 1995, and in 1990 was declared “Washingtonian of the Year” by Washingtonian Magazine for helping to found the Children’s Inn, a temporary home for children undergoing treatment at the National Institutes of Health and their families.

Claire Pomeroy, M.D., M.B.A.

An executive officer from a UC with a medical school (5 of 5), appointed by UC Davis Chancellor

Claire Pomeroy, M.D, is Vice Chancellor for Human Health Sciences at UC Davis and Dean of the UC Davis School of Medicine, is an expert in infectious diseases and a professor of internal medicine and microbiology and immunology. She oversees the UC Davis Health System and all its academic, research and clinical programs, including the 800-member physician group known as UC Davis Medical Group and the 576-bed acute-care hospital known as UC Davis Medical Center. With an operating budget of nearly \$800 million, patient visits of nearly 900,000, and more than \$100 million in outside research funding, UC Davis Health System is a major contributor to the health care and economy of the Sacramento region.

Dr. Pomeroy joined UC Davis in 2003 as executive associate dean of the School of Medicine. In that role, she guided the development of a new strategic plan, enhanced the infrastructure for research and educational programs, and integrated the operations of the medical school and teaching hospital. Dr. Pomeroy leads an active research team studying host responses to infectious diseases. She has published over 100 articles and book chapters and edited two books. She currently serves on grant review study sections for the National Institutes of Health and the Department of Veterans Affairs.

With special expertise in HIV/AIDS, she is a long-time advocate for patients with HIV/AIDS and has a special interest in health-care policy. She also has led efforts to advance electronic health records to improve health-care quality. Dr. Pomeroy is a member of the Board of Directors of the MIND Institute at UC Davis and of the CARES clinic in Sacramento.

She received bachelor’s and medical degrees from the University of Michigan, then completed her residency and fellowship training in internal medicine at the University of Minnesota. She also earned an MBA from the University of Kentucky.

Francisco J. Prieto, M.D.

***Patient Advocate (4 of 10), appointed by the Treasurer
Type I Diabetes***

Diabetes research expert, Francisco J. Prieto, M.D., serves as President of the Sacramento Sierra Chapter of the American Diabetes Association. He previously chaired the Association’s Professional Education Committee and currently chairs the committee for “Tour de Cure”, the

ADA's annual bicycling event. He has been active in Diabetes care, patient and professional education and exercise promotion throughout his career.

Dr. Prieto was born in Chicago Illinois, one of 9 children of Jorge Prieto MD and Luz Maria Prieto. He received his Bachelor of Sciences with majors in Biology and History from the University of Illinois – Chicago, where he was undergraduate representative on the UIC Chancellor Search Committee. He received his M.D degree from the university of Minnesota, then completed a residency in Family Medicine at the University of Arizona. He served 3 years in the National Health Service Corps, and was an Associate Clinical Professor at the Univ. of Arizona.

Dr. Prieto practices with Sutter Medical Group in Elk Grove, and is an assistant Clinical Professor at the Univ. of California, Davis.

Carmen Puliafito, M.D., M.B.A.

An executive officer from a California University (4 of 4), appointed by the Governor

Prior to assuming the deanship of the Keck School of Medicine on November 1, 2007, Dr. Puliafito served as director of the Bascom Palmer Eye Institute and chair of the Department of Ophthalmology of the University of Miami Miller School of Medicine. Before joining Bascom Palmer, Dr. Puliafito served as founding director of the New England Eye Center and chair of the Department of Ophthalmology at Tufts University from 1991 to 2001.

Dr. Puliafito started his career at the Massachusetts Eye and Ear Infirmary at Harvard Medical School, where he was founder of the Laser Research Laboratory, director of the Morse Laser Center, a member of the Retina Service, and associate professor of ophthalmology at Harvard Medical School. He is recognized as co-inventor of the technology of optical coherence tomography (OCT), and was the first ophthalmologist to use this technology to study the human macula in health and disease. For his work on OCT, Dr. Puliafito was awarded (along with James Fujimoto and Eric Swanson) the 2002 Rank Prize -- the world's most prestigious award in optoelectronics.

Throughout his career, Dr. Puliafito has been an innovator, most recently participating in the introduction of bevacizumab (Avastin) for the treatment of retinal disorders. He was the first to describe the use of a semiconductor diode laser for retinal photocoagulation, and pioneered basic science research in excimer laser photoablation and optical breakdown and photodisruption.

Dr. Puliafito has a BS from Harvard University, a Doctor of Medicine, magna cum laude from Harvard Medical School and an MBS from the Wharton School of Business at the University of Pennsylvania.

Robert A. Quint, M.D., FSCAI

***Patient Advocate 5 of 10), appointed by the Treasurer
Heart Disease***

Robert A. Quint, M.D., FSCAI, has served California as a notable physician specializing in cardiology since 1971. In addition to having a private practice, Dr. Quint also holds a staff appointment at O'Connor Hospital in San Jose. Over his 25-year tenure at O'Connor Hospital, he has been Director of the Department of Cardiology and Vascular Services and a member of the Cardiovascular Quality Assurance Committee. He is a charter member and founding fellow of the Society for Cardiac Angiography and Interventions (SCAI) and the SCAI's Credentials Committee. In his involvement with the American Heart Association (AHA), he serves on the AHA's Scientific Council and AHA's Council on Atherosclerosis. His other professional memberships include the Medical Advisory Board of the Scimed Lifesystems, Inc., the United States Congressional Advisory Board, and the American Professional Practice Association.

Dr. Quint began his history of public service in the military, working as a cardiologist and internist at the Valley Forge Hospital in Phoenixville, Pennsylvania. As a member of the U.S. Army Medical Corps, he was an internist and cardiologist at the 8th Field Hospital in Nha Trang, Vietnam.

In contributing to academic medical knowledge, Dr. Quint has written several articles for such publications as the American Journal of Cardiology and the Journal of Thoracic Cardiovascular Surgery. For fourteen years, he was a clinical instructor on the voluntary clinical faculty at the Stanford University School of Medicine. His medical work has taken him as far as Iran, Sri Lanka, and Japan to present and lecture.

Dr. Quint obtained his Bachelor of Science degree in Biology from the University of Notre Dame and his medical degree from Ohio State University School of Medicine. He completed both his internship and his residency training at the University of Texas Medical Branch, John Sealy Hospital. He also completed two fellowships, in internal medicine and invasive cardiology, at the Cleveland Clinic in Cleveland, Ohio.

John C. Reed, M.D., Ph.D.

An executive officer from a California Research Institute (4 of 4), appointed by the Controller

Dr. John C. Reed is President & Chief Executive Officer of the Burnham Institute for Medical Research, a non-profit biomedical research institute with over 600 employees. Dr. Reed received his undergraduate education from the University of Virginia (BA/Biochemistry), where he graduated Phi Beta Kappa in 1980, then entered the Medical School of the University of Pennsylvania (MD, PhD), where he graduated in Alpha Omega Alpha in 1986.

In 1992, Dr. Reed joined the Burnham Institute, and was promoted to Scientific Director in 1995, prior to becoming President & CEO in 2002. He conceived of and was instrumental in launching the formation of a new research center at the Burnham Institute devoted to research on aging and neurodegenerative diseases. Dr. Reed also served as Deputy Director of the Burnham Institute's NCI-sponsored Cancer Center from 1994 to 2002, and briefly as interim Director in 2002. He additionally holds adjunct Professorships at the University of California San Diego and San Diego State University.

Dr. Reed remains an active scientist, currently directing a laboratory of ~40 persons at the Burnham Institute. His research interests have focused primarily on cancer, but he has also made important contributions in the areas of AIDS, autoimmunity, stroke and other diseases. He has been a pioneer in delineating the fundamental mechanisms that regulate programmed cell death, a process by which cells in the body commit suicide through activation of a genetically controlled program. He has the distinction of having published more papers on programmed cell death (also known as “apoptosis”) during the past decade than any other scientist worldwide, according the Institute for Scientific Information.

Dr. Reed currently serves on the editorial boards of over 12 scientific journals. He has also served as an advisor to the National Cancer Institute (NCI), American Cancer Society (ACS), and the American Association for Cancer Research (AACR). He is the recipient of numerous awards for his research accomplishments, and has been awarded over 65 research grants by a variety of funding agencies, including the National Institutes of Health, the NCI, the ACS, the Leukemia Society of America, CaP-CURE, ABC2, and the Susan B Komen Breast Cancer Foundation.

Duane J. Roth

Vice-Chair of the Governing Board of the CIRM (Bylaws: elected pursuant to Art. VIII, Sec. 2 of the ICOC Bylaws); an executive officer of a Commercial Life Science Entity (4 of 4)

Duane J. Roth is Chairman and Chief Executive Officer of Alliance Pharmaceutical Corp., a research and development company focused on oxygen based therapeutics. Mr. Roth also serves as Chief Executive Officer of CONNECT. CONNECT is the globally recognized, non-profit organization fostering entrepreneurship in the San Diego region by catalyzing, accelerating, and supporting the growth of the most promising technology and life sciences businesses.

Prior to founding Alliance, Mr. Roth held senior management positions at American Home Products (now Wyeth) and Johnson & Johnson operating companies. He has served as a member of the Board of Directors and executive committees of the Biotechnology Industry Organization (BIO), the California Healthcare Institute (CHI), and BIOCUM (past Chair).

Mr. Roth serves on a number of advisory committees and boards of the University of California, including the President’s Board on Science and Innovation, the UCSD Cardiovascular Center (past Chair), the San Diego Science and Technology Council, the UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences, the UCSD Rady School of Management, the Preuss Charter School (Chair), and the UC San Diego Foundation Board (past Chair). Mr. Roth is active in the San Diego community, serving on the board of the San Diego Regional Economic Development Corporation (past Chair), the San Diego Regional Chamber of Commerce, the Lincoln Club of San Diego (past Chair), the San Diego State University College of Business (past Chair), and as co-Chair of the Regional Housing Task Force on Affordable Housing. Mr. Roth is a member of Governor Arnold Schwarzenegger’s California Commission For Jobs and Economic Growth. He is a graduate of Iowa Wesleyan College, where he serves as a trustee.

Joan Samuelson, J.D.

***Patient Advocate (6 of 10), appointed by the Controller
Parkinson's Disease***

Joan Samuelson began her career in public policy on the staff of U.S. Senator John Tunney (D-Calif.). She later worked with the California Coastal Commission while she pursued her law degree. The 1987 diagnosis of Parkinson's disease led her to abandon the practice of law and create an advocacy voice for the Parkinson's community, seeking greater research freedom, increased research funding and a faster cure. Samuelson founded the Parkinson's Action Network in 1991 and successfully engaged Congress and the executive branch via a series of national patient advocacy campaigns, resulting in 1997 enactment of the seminal Morris K. Udall Parkinson's Research Act, and federal appropriations that combined to increase Parkinson's research funding tenfold.

A lifetime Californian, Samuelson played an active role in the campaign resulting in the 2004 passage of California's Proposition 71 Stem Cell Research and Cures Act. She currently holds the "Parkinson's advocate" seat on the Act's 29-member Independent Citizens Oversight Committee, the governing board, and serves as Vice Chair of the Research Funding Working Group.

Samuelson has served in numerous advisory capacities on biomedical research and health policy, including as an Independent Report Reviewer for the 2004 Report of the National Academies' of Science Institute of Medicine on NIH Extramural centers Programs; on the Advisory Committee to the Director, National Institute of Environmental Health Sciences; and in 2004 as Patient Advocate on the Medicare Consumer Advisory Committee. She has served as an advisor to research organizations including the NIEHS Collaborative Center for Parkinson's Disease Environmental Research, the Parkinson's Institute and the Environmental and Occupational Health Sciences Institute at UMDNJ/Robert Wood Johnson Medical School.

Among those recognizing Samuelson's work are the American Society for Neural Therapy and Repair, 2008 [Molly and Bernard Sanberg Lifetime Achievement Award "for Significant Contributions to the field of Brain Repair"]; California Lutheran University, 2007 Doctor of Humane Letters honoris causa ["in recognition of advocacy for Parkinson's research"]; the Parkinson's Institute, 2003 ["Outstanding Achievement"]; Research!America, 2000 ["Exceptional Contributions as a Volunteer Advocate for Medical Research"]; Community Resources for Independence, 2000, Dove Award ["in recognition of Outstanding Contributions to Persons with Disabilities"]; Alumni Association, University of California, Berkeley, School of Law [1996 Distinguished Service Award]; California Lawyer Magazine [1996 "Legal Eagles," 25 California lawyers "who made new law or policy or changed the course of national events"]; and California Federation of Business and Professional Women, 1993 [Hall of Fame, Government].

Samuelson is a graduate of the University of California at Los Angeles [B.A. cum laude, Public Service, 1972] and the School of Law at the University of California at Berkeley [Juris Doctor, 1977]. She is a member of the California Bar. Before leaving the active practice of law for patient advocacy, Samuelson specialized in civil litigation and alternative dispute resolution.

David Serrano Sewell, J.D.

***Patient Advocate (7 of 10), appointed by the Lt. Governor
MS/ALS***

A Los Angeles native, David was raised in a household that valued public service, volunteer work, and political involvement. David has commented that “those early experiences were important, they taught me the value of caring for others, hard work, and loyalty.”

Currently, David is employed as a Deputy City Attorney in the S.F. City Attorney’s Office, assigned to the Port of San Francisco. In this capacity, David advises the Port on transactional, land use, permitting, and trust law.

Moving to San Francisco in 1989 to attend San Francisco State University, he served as Student Body President in 1993.

David is a veteran of numerous local and statewide campaigns. In 1995, he served as an aide to Mayor Willie L. Brown, Jr., working on land use and permitting issues. In time, he decided to attend Golden Gate University School of Law. During law school, he was a member of Law Review, was awarded the Witkin and Cali Award in Federal Administrative Law, was as an extern in the chambers of Judge Maxine M. Chesney, U.S. District Court, Northern District of California. He was admitted to the State Bar in June, 2003.

He has served on the City’s Ethic’s and Elections commission, respectively, and the board of directors of BRAVA! For Women in Arts, a community based theatre group focusing on Latina playwrights.

After his own diagnosis of MS, he began volunteering with the Northern California Chapter of the National Multiple Sclerosis Society, assisting the organization in their advocacy efforts. David firmly believes “that advocacy is crucial to ensuring that precious research dollars are spent in a manner that will benefit patients.

Jeff Sheehy

***Patient Advocate (8 of 10), appointed by the California Senate President Pro Tempore
HIV/AIDS***

Jeff Sheehy is director for communications at the AIDS Research Institute at UCSF. He is a longtime HIV/AIDS and gay civil rights activist and a person living with HIV. Sheehy most notably worked on Survive AIDS’ project advocating for organ transplants for people with HIV. Survive AIDS, in collaboration with Assemblywoman (now Senator) Carole Migden, obtained funds for organ transplants for people with HIV. This initiative has not only saved lives of Californians with HIV/AIDS who needed transplants, but also led to a NIH funded protocol that is performing solid organ transplants in people with HIV at sites across the country.

In 1996, he and two colleagues conceived, drafted and lobbied through San Francisco’s historic Equal Benefits Ordinance, which requires that companies contracting with the City provide the domestic partners of employees the same benefits that spouses of employees receive. To support the

legislation, he founded and led Equal Benefits Advocates, which conducted the successful national boycott of United Airlines that resulted in United, American, and US Airways offering domestic partner benefits to their employees worldwide in 1999. To date, over 3,500 companies have complied with the law. And, an estimated 50,000+ lesbians and gay men around the country have now obtained health insurance and other benefits for their domestic partners due to this law.

From 1998 to 2000, Sheehy served as a victim advocate for the San Francisco District Attorney. In that position, he assisted same-sex victims of domestic violence and hate crimes and conducted an advanced officer training class in same-sex domestic violence at the San Francisco Police Academy. Sheehy was appointed HIV/AIDS advisor to San Francisco Mayor Gavin Newsom in 2004.

Sheehy has been the recipient of the Cape Crusader Award from Equality California, the HRC Leadership Award from The Human Rights Campaign, the Tomas Fabregas AIDS Hero Award presented at San Francisco's AIDS Candlelight March in 2001 and was featured in OUT Magazine's OUT 100 list of the most influential members of the LGBT community in 1999. He received a bachelor's degree in history from the University of Texas in Austin.

Jonathan Shestack

***Patient Advocate (9 of 10), appointed by the Speaker of the Assembly
Mental Health***

Jonathan Shestack co-founded The Cure Autism Now Foundation (CAN) in 1995. Having invested over 25 million dollars in autism research, CAN is now the largest non-federal funder of biological research in autism. Over the years, CAN has been a key player responsible for building the autism research field from scratch and recruiting hundreds of scientists.

CAN, in an effort led by Shestack, was also responsible for quadrupling federal spending on autism through the passage of the Pediatric Health Care Act of 2000, the establishment of 8 new Centers of Excellence in Autism and a new 2 million dollar a year Patient and Physician Awareness program coordinated through the CDC.

CAN funds and operates AGRE, the Autism Genetic Resource Exchange, the only totally open gene bank for autism and the largest collection in the world. It has played an important part in setting NIMH standards on issues of broad data sharing and scientific collaboration.

In 2002, Shestack was appointed as one of three public members to the NIH Internal autism coordinating committee, which includes the heads of four NIH institutes, and he serves on the Subcommittee on Screening and Early Diagnosis.

Shestack also serves on two bio-ethics task forces, a Department of Energy group on issues of ethics and gene patenting, and the Stanford University Center on Integrating Ethics and Genetic Research.

Shestack has a particular interest in mental health issues, the rights and expectations of vulnerable populations, in particular children and the mentally ill. Beyond his involvement in autism, he has

been active in promoting science in the public interest, scientific collaboration, research resource creation and broad data sharing.

In his professional life Shestack is a movie producer currently based at Warner brothers. He was president of production of Artisan Entertainment and Executive Vice President of Beacon Entertainment where he produced AIR FORCE ONE, FAMILY MAN and BRING IT ON.

He is married to Portia Iversen co-founder of Cure Autism Now and is the father of three children, one of whom is affected by autism.

Oswald Steward, Ph.D.

***Patient Advocate (10 of 10), appointed by the Governor
Spinal Cord Injury***

Oswald Steward, Ph.D., is known for his research on how nerve cells create and maintain their connections with each other, and how these synapses are modified after injury. He has also conducted research on how genes influence nerve cell regeneration, growth and function and how physiological activity affects nerve cell connections.

Dr. Steward is currently the chair and director of the Reeve-Irvine Research Center for Spinal Cord Injury at the University of California, Irvine (UCI) and also professor of anatomy and neurobiology. He serves on the board of the Christopher Reeve Paralysis Foundation and also serves as the chair of its Science Advisory Council. Dr. Steward was also the chair of a National Institutes of Health (NIH) neurobiology review group and served on the NIH's Spinal Cord Injury Planning Committee. Prior to joining the faculty at UC Irvine, he was Professor of Neuroscience and Neurosurgery at the University of Virginia, where he served as Chair of the Department of Neuroscience.

Steward is a recipient of the NIH Research Career Development Award, the Jacob Javitz Neuroscience Investigator Award and the Distinguished Investigator Award from the National Alliance for Research on Schizophrenia and Depression. He earned a doctorate degree in psychobiology from the University of California, Irvine and a bachelor's degree in psychology from the University of Colorado, Boulder.

Art Torres, J.D.

Vice-Chair of the Governing Board of the CIRM (Statutory: elected pursuant to Health & Saf. Code, section 125290.20(a)(6))

In a career spanning more than three decades, Senator Art Torres (Ret.) has distinguished himself as a public servant determined to tackle complex policy issues and stand up for those without a voice. He has been involved in crucial bipartisan initiatives in the fields of healthcare, education, the environment, and human rights and has been a leader in the public, private, and non-profit sectors.

Since 1996, Senator Torres has served as the Chairman of the California Democratic Party, where he manages three offices, twenty-four full-time employees, and an operating budget of \$2 million.

During each two-year election cycle, he is responsible for raising millions for statewide campaigns and overseeing up to 1,500 additional staff members.

In 2004, he led the Party in supporting Proposition 71 and ensured the measure was prominently mentioned in over one million statewide mailings and Election Day “Get Out the Vote” efforts.

Senator Torres has served on the Board of Directors of the AIDS Healthcare Foundation and is currently on the Board of "One Legacy," an organ transplant foundation in Los Angeles in conjunction with Dr. Robert Mendez and Dr. Rafael Mendez.

He is a colon cancer survivor since 2006. His 88-year-old Mother Julia is a breast cancer survivor since 1994. He and his sister Marina, a Calistoga Elementary School teacher for over 28 years, walk with their Mother every year in the "Relay for Life" to help raise funds for breast cancer awareness and to honor their Father, Arthur who passed away from kidney cancer.

He secured direct funding for university research programs as well as structural support for industry-sponsored work, and funded early HIV/AIDS research in conjunction with Dr. Marcus Conant, before most public officials recognized the severity of the epidemic.

Senator Torres previously served twenty years in the California Legislature, eight as a member of the State Assembly and twelve as a State Senator. Well respected for his policy acumen, Torres chaired the Senate Insurance Committee, the Assembly Health Committee, the Senate Joint Committee on Science and Technology, the Senate Select Committee on the Entertainment Industry, the Senate Committee on Tourism and Aviation, and the Joint Committee on Refugees.

A longtime leader on health issues, Senator Torres co-authored the unprecedented and extremely successful California Clean Water Drinking Act, known as Proposition 65, and established a cancer reporting system in 15 Central Valley and coastal communities to help hospitals form a computer network.

He also fought against water contamination, pesticide poisoning, and exposure to toxic chemicals and asbestos. His passion to deter pesticide poisoning came from working closely with Cesar Chavez in the early 1970's as a member of the United Farm Workers Union. He also advocated for insurance reimbursement for breast cancer treatments.

His legislative accomplishments also include the most successful anti high school dropout law in California's history, SB 65. He also created the only national Japanese American Museum located in Little Tokyo, Los Angeles and co-authored legislation to create the Museum on Tolerance in Los Angeles.

Recognized as a leader with important diplomatic skills, he led international delegations to release Vietnamese prisoners from "education camps" in Hanoi, Vietnam and to assist Soviet Jewish refugee efforts in the former Soviet Union. Further, he was asked by the Vatican to assist in drafting Pope John Paul II's 1990 environmental message. Along with Nobel Laureates and international environmental leaders they presented their document to the Holy Father in the Vatican before it was delivered in St. Peter's Square on New Year's Day.

A well-respected business leader, Senator Torres was President of Cordoba International, an engineering consulting firm in Los Angeles, and served as Vice President at Montgomery Asset Management in San Francisco. He was also appointed by the United States Senate to the Commission on International Migration and Cooperative Economic Development which presented its recommendations on immigration reform to then President George Bush in 1990.

Senator Torres has also served on the Board of the Latino Community Foundation, the San Francisco Ballet, and the Advisory Board of The Princeton Review, and currently sits on the Board of Governors for “Heal the Bay” in Santa Monica.

He holds a Bachelor's Degree from UC Santa Cruz and a Juris Doctorate degree from UC Davis School of Law. He also served as a John F. Kennedy teaching fellow at Harvard University's John F. Kennedy School of Government.

He is the proud father of Joaquin Torres, a graduate of Stanford University and the New York University Tisch Graduate School of Acting; currently an actor in New York; and Danielle Torres, a graduate of the Joint School of Music & Business Music Industry major program at the University of Southern California in Los Angeles (USC), currently employed with the William Morris Agency in Beverly Hills, California.

###